BVNKF.US Bavarian Nordic A/S

Healthcare Biotechnology USA Stocks
37.26 USD
Close of Nov 13, 2026
27.69 37.26
Market cap
USD 2.78B
P/E
12.3x
P/B
1.41x
ROE
11.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BVNKF.US undervalued?

Graham number
Price37.26
Graham value42.55
Discount12.4%

BVNKF.US trades 12.4% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bavarian Nordic A/S fundamental analysis

No fundamental analysis for Bavarian Nordic A/S yet.

Bavarian Nordic A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN …

Full company profile